Revenue recognition reserve target exclusivity period. Revenue Recognition Reserve Target Exclusivity Period Revenue recognition, reserve target exclusivity period Entity Address, City or Town Entity Address, City or Town Fair Value Disclosures [Abstract] Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Liabilities Research and Development Expense, Policy [Policy Text Block] Research and Development, Net Net Cash Provided by (Used in) Financing Activities [Abstract] FINANCING ACTIVITIES: Amendment Flag Amendment Flag Purchase of property and equipment in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Contra expense included in research and development expense. Contra Expense Included In Research And Development Expense Contra expense included in research and development expense Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Share-based compensation number of shares authorized Vinbiocare. Vinbiocare [Member] Vinbiocare [Member] September two thousand and twenty one lease agreement. September Two Thousand And Twenty One Lease Agreement [Member] September 2021 Lease Agreement [Member] COVID-19 vaccine development. C O V I D Nineteen Vaccine Development [Member] COVID-19 Vaccine Development Operating Lease, Right-of-Use Asset Operating lease right-of-use asset, net Debt Instrument, Collateral Debt instrument, collateral Document Quarterly Report Document Quarterly Report Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Billing received amount related to clinical trial. Billing Received Amount Related to Clinical Trial Billing received amount from third party related to clinical trial Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Equity Method Investments Equity-method investment Statement [Table] Statement [Table] Operating Lease, Liability, Noncurrent Operating lease liability, net of current portion Collaboration Partner Cure Vac entered into Co-Development Agreement. Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Number of Operating Segments Number of operating segment for research and development Royalty payment term description. Royalty Payment Term Description Royalty payment term description Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for future issuance Janssen. Janssen [Member] Janssen [Member] Commitment and contingencies. Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Product and Service [Axis] Product and Service Employee-related Liabilities, Current Accrued compensation Employee-related Liabilities, Current, Total Share-Based Payment Arrangement, Option [Member] Stock Option [Member] Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term Liabilities and Equity Total liabilities and stockholders’ equity Payments for (Proceeds from) Tenant Allowance Tenant improvement allowance Plan Name [Domain] Plan Name us-gaap:OtherLiabilitiesCurrent Other Liabilities, Current Collaboration agreement contractual term. Collaboration Agreement Contractual Term Contractual term Upfront fee received. Upfront Fee Received Upfront fee received Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Liquidity. Liquidity Policy Policy [Text Block] Liquidity Borrowings under Guaranteed Investment Agreements Term loan draw down Potential Principal Repayments Of Debt Instrument. Potential Principal Repayments Of Debt Instrument Potential principal repayment of loan Sale of Stock [Domain] Sale of Stock Liabilities, Current Total current liabilities Lessee, Operating Lease, Liability, to be Paid, Year Three 2025 Contract with customer asset additions for revenue recognized. Contract With Customer Asset Additions For Revenue Recognized Contract Assets, Additions for revenue recognized from billings Manufacturing capacity fees Manufacturing Capacity Fees Accrual Current Manufacturing capacity fees accrual current. Cystic Fibrosis Foundation Therapeutics, Inc. Cystic Fibrosis Foundation Therapeutics Inc [Member] Cystic Fibrosis Foundation [Member] Increase (Decrease) in Contract with Customer, Liability Deferred revenue Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Investment, Name [Domain] Investment, Name Entity Small Business Entity Small Business Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of the period Cash, cash equivalents and restricted cash at beginning of the period Total cash, cash equivalents and restricted cash shown in the statement of cash flows Cash and cash equivalents, including restricted cash Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Payments for matching funds for remaining budgeted costs. Payments For Matching Funds For Remaining Budgeted Costs Payments for matching funds for remaining budgeted costs Assets, Current Total current assets Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Summary of Changes in Balances of Contract Assets and Contract Liability Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2022 Weighted-average shares outstanding, basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total February two thousand and twenty lease agreement. February Two Thousand And Twenty Lease Agreement [Member] February 2020 Lease Agreement [Member] Revenue [Line Items] Revenue [Line Items] Revenue. City Area Code City Area Code Share-Based Payment Arrangement [Abstract] Liabilities Total liabilities Private Placement [Member] Document Period End Date Document Period End Date Disbursement period three. Disbursement Period Three [Member] Disbursement Due July 2020 [Member] Lease Contractual Term [Domain] Lease Contractual Term Construction in Progress [Member] Construction in progress [Member] Research Collaboration and Exclusive License Agreement. Research Collaboration And Exclusive License Agreement [Member] Research Collaboration And Exclusive License Agreement [Member] Lessee, Operating Lease, Renewal Term Operating lease extended additional term Statistical Measurement [Axis] Statistical Measurement Thereafter Lessee operating lease liability payments due after year four. Lessee Operating Lease Liability Payments Due After Year Four Related Party [Axis] Related Party Assets Total assets Contract with Customer, Asset, after Allowance for Credit Loss Contract Assets, Balance Contract Assets, Balance Contract with Customer, Asset, after Allowance for Credit Loss, Total Maximum sales required for loans forgivable . Maximum Sales Required For Loans Forgivable Maximum LUNAR-COVID 19 sales required for Loans forgivable Loan and security agreement. Loan And Security Agreement [Member] Loan and Security Agreement [Member] Long-Term Debt, Excluding Current Maturities Long-term debt, net of current portion Long-term Debt, Excluding Current Maturities, Total Net loss per share, diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Dividends Dividends declared or paid Dividends, Total Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Fiscal Period Focus Document Fiscal Period Focus Prepayment fee percentage. Prepayment Fee Percentage Prepayment fee percentage Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Description of Business, Basis of Presentation and Summary of Significant Accounting Policies Increase (Decrease) in Accounts Receivable Accounts receivable APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Share-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Adjustments to transaction price. Adjustments To Transaction Price Adjustments to transaction price Counterparty Name [Domain] Counterparty Name Operating Lease, Liability Total operating lease liabilities Operating Lease, Liability, Total Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Contract with customer asset deductions for cash collections. Contract With Customer Asset Deductions For Cash Collections Contract Assets, Deductions for cash collections Statement of Financial Position [Abstract] Ultragenyx. Ultragenyx [Member] Ultragenyx [Member] Development and option agreement date. Development And Option Agreement Date Development and option agreement date Entity File Number Entity File Number Scenario [Domain] Scenario Statement of Cash Flows [Abstract] Balance Sheet Related Disclosures [Abstract] Contra expense remaining amount included in accrued expenses. Contra Expense Remaining Amount Included In Accrued Expenses Contra expense remaining amount included in accrued expenses Proceeds from Issuance of Debt Net increase in indebtedness Proceeds from debt Geographical [Domain] Geographical Statistical Measurement [Domain] Statistical Measurement Statement of Stockholders' Equity [Abstract] Debt Instrument, Date of First Required Payment Loan first principal payment extended maturity date Sale of Stock [Axis] Sale of Stock Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive loss: Stockholders' Equity Note [Abstract] Equity Method Investment, Ownership Percentage Equity method ownership percentage Fair Value Disclosures [Text Block] Fair Value Measurements Equity Method Investment, Aggregate Cost Investment in joint venture Accounting Standards Update 2014-09 [Member] ASC 606 [Member] Proceeds from Stock Options Exercised Proceeds from exercise of stock options Long-Term Debt, Type [Axis] Long-term Debt, Type Clinical accruals current. Clinical Accruals Current Clinical accruals October 2017 lease amendment. October Two Thousand And Seventeen Lease Amendment [Member] October 2017 Lease Amendment [Member] Property, Plant and Equipment [Table Text Block] Summary of Components of Property and Equipment, Net Revenue from Contract with Customer [Text Block] Revenue Preclinical milestone payment received Preclinical Milestone Payment Received Preclinical milestone payment received. Summary of significant accounting policy. Summary Of Significant Accounting Policy [Line Items] Summary Of Significant Accounting Policy [Line Items] Western Alliance Bank. Western Alliance Bank [Member] Western Alliance Bank [Member] Investment Owned, Balance, Shares Number of shares owned Disbursement period two. Disbursement Period Two [Member] Disbursement Due April 2020 [Member] Contingent Grants [Member] Contingent grants member. Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Details Payments to Acquire Interest in Joint Venture Cash consideration paid for equity interest in joint venture Weighted-average shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Other. Other [Member] Other [Member] Computer Equipment [Member] Computer and software [Member] General and Administrative Expense [Member] General and Administrative [Member] Current Fiscal Year End Date Current Fiscal Year End Date Revenue recognition potential milestone revenue recognized. Revenue Recognition Potential Milestone Revenue Recognized Revenue recognition potential milestone revenue recognized 2021 Inducement equity incentive plan. Twenty Twenty One Inducement Equity Incentive Plan [Member] 2021 Inducement Equity Incentive Plan [Member] Entity Address, Address Line One Entity Address, Address Line One Deferred Revenue, Noncurrent Deferred revenue, net of current portion Deferred Revenue, Noncurrent, Total Accrued Liabilities, Current [Abstract] Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information Restricted Cash, Noncurrent Non-current restricted cash Non-current restricted cash Income Tax Expense (Benefit) Income tax expense Income Tax Expense (Benefit), Total Income Tax Disclosure [Text Block] Income Taxes Payments to Acquire Property, Plant, and Equipment Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Revenue, Remaining Performance Obligation, Amount Remaining performance obligation Income Tax Disclosure [Abstract] Number of reserved vaccine doses. Number Of Reserved Vaccine Doses Number of reserved vaccine doses Stock Issued During Period, Shares, New Issues Issuance of common stock, net of issuance costs (in shares) Issuance of common stock Pre-launch inventory policy. Pre Launch Inventory Policy Policy [Text Block] Pre-Launch Inventory Investment Owned, Percent of Net Assets Percentage of owned shares Debt Instrument, Collateral Amount Debt instrument, collateral amount Contract with Customer, Liability, Revenue Recognized Deductions for promised services provided in current period Upfront payment received. Upfront Payment Received Upfront payment received Operating Income (Loss) Loss from operations Lessee, Operating Lease, Option to Extend Lessee, operating leases, option to extend Related Party [Domain] Related Party Debt Instrument, Increase, Accrued Interest Accrued interest added to principal debt balance Scenario [Axis] Scenario Revenue [Table] Revenue [Table] Revenue. Research and Development in Process Non-cash charge recorded in acquired in-process research and development expense Acquired in-process research and development expense Entity Filer Category Entity Filer Category ADAIR Technology. A D A I R Technology [Member] ADAIR Technology [Member] February two thousand and twenty one lease agreement. February Two Thousand And Twenty One Lease Agreement [Member] February 2021 Lease Agreement [Member] Operating Expenses Total operating expenses Entity Current Reporting Status Entity Current Reporting Status Contra research and development expense. Contra Research And Development Expense Contra research and development expense recognized Research collaboration and license agreement. Research Collaboration And License Agreement [Member] Research Collaboration And Exclusive License Agreement [Member] Number of performance obligations. Number Of Performance Obligations Number of performance obligations Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Stockholders' Equity Attributable to Parent Balance Balance Total stockholders’ equity Inventory, Cash Flow Policy [Policy Text Block] Statement of Cash Flows Entity Tax Identification Number Entity Tax Identification Number Income Statement Location [Axis] Income Statement Location Common stock: $0.001 par value; 60,000 shares authorized; 26,434 issued and outstanding at June 30, 2022 and 26,372 issued and outstanding at December 31, 2021 Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Equipment [Member] Research equipment [Member] Equity Components [Axis] Common Stock [Member] Accounting Standards Update [Domain] Accounting Standards Update Agreement amount agreed to fund. Agreement Amount Agreed To Fund Amount agreed to fund Leases [Abstract] Contract with Customer, Liability Contract Liabilities, Balance Contract Liabilities, Balance Deferred revenue Contract with Customer, Liability, Total Disaggregation of Revenue [Table] Disaggregation Of Revenue [Table] Entity Emerging Growth Company Entity Emerging Growth Company Operating Expenses [Abstract] Operating expenses: Grant one. Grant One [Member] Grant 1 Revenue [Policy Text Block] Revenue Recognition CureVac AG. Cure Vac A G [Member] CureVac [Member] Schedule of Stock by Class [Table] Schedule Of Stock By Class [Table] Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals Inc [Member] Alexion [Member] Investment, Name [Axis] Investment, Name Payments for Advance to Affiliate Payments for advance Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction, Total Document Transition Report Document Transition Report Upfront fee/consideration. Upfront Fee And Consideration Upfront fee/consideration Equity method investment, sale of common stock Sale of Stock, Number of Shares Issued in Transaction Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Vallon Pharmaceuticals, Inc. Vallon Pharmaceuticals Inc [Member] Vallon Pharmaceuticals, Inc. [Member] Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current, Total Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Net Income (Loss) Attributable to Parent Net loss Net loss Operating Lease, Liability, Current Current portion of operating lease liability Warrant fee payable. Warrant Fee Payable Warrant fee payable Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Monthly base rent. Monthly Base Rent Monthly base rent Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of Maturities of Long-term Debt Entity Registrant Name Entity Registrant Name Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Debt Instrument, Maturity Date Loan maturity date Other accrued research and development expenses. Other Accrued Research And Development Expenses Other accrued research and development expenses Share-Based Payment Arrangement, Noncash Expense Share-based compensation expense Share-based Payment Arrangement, Noncash Expense, Total Statement of Comprehensive Income [Abstract] Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Award Type [Domain] Award Type Statement [Line Items] Statement [Line Items] Title of 12(b) Security Title of 12(b) Security Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Percentage required to be maintained in consolidated unrestricted cash. Percentage Required To Be Maintained In Consolidated Unrestricted Cash Percentage required to be maintain in consolidated, unrestricted cash Common Stock [Member] Common Stock [Member] Net Cash Provided by (Used in) Operating Activities [Abstract] OPERATING ACTIVITIES: Equity Component [Domain] Equity Component Revenue from Contract with Customer, Excluding Assessed Tax Revenue Total revenue Revenue from Contract with Customer, Excluding Assessed Tax, Total Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Cash and Cash Equivalents and Restricted Cash Entity Address, State or Province Entity Address, State or Province Lessee, Operating Lease, Liability, to be Paid, Year Four 2026 Geographical [Axis] Geographical Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Document Type Document Type Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Disbursement period four. Disbursement Period Four [Member] Disbursement Due October 2020 [Member] Entity Shell Company Entity Shell Company Share-Based Payment Arrangement, Expense Share-based compensation expenses Share-based compensation expenses Interest Expense, Long-Term Debt Interest expense related to long-term debt Interest Expense, Long-term Debt, Total Grants Receivable Grant awarded Revenue, Practical Expedient, Remaining Performance Obligation, Description Revenue, practical expedient description Security Exchange Name Security Exchange Name Revenue from Contract with Customer [Abstract] Class of Stock [Line Items] Class Of Stock [Line Items] Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Debt Instrument, Interest Rate, Effective Percentage Loan accrues interest rate per annum, percentage Commitments and Contingencies Disclosure [Abstract] Operating Lease, Cost Operating lease costs Lessee, Operating Lease, Liability, Maturity [Table Text Block] Remaining Payments of Operating Lease Liability Recently Issued Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Percentage of equity interest in joint venture. Percentage Of Equity Interest In Joint Venture Percentage of equity interest in joint venture Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Debt Disclosure [Text Block] Debt Proceeds from Issuance of Long-Term Debt Proceeds from long-term debt agreement Proceeds from Issuance of Long-term Debt, Total Deferred Revenue, Current Deferred revenue Deferred Revenue, Current, Total Net Cash Provided by (Used in) Investing Activities [Abstract] INVESTING ACTIVITIES: Vinbiocare agreement. Vinbiocare Agreement [Member] Vinbiocare Agreement [Member] Purchase of common stock, shares Common Stock, Shares, Issued, Total Issuance of Shares Common stock, shares issued Minimum [Member] Minimum [Member] LUNAR-CF. L U N A R C F [Member] LUNAR-CF [Member] Stock Issued During Period, Value, Issued for Services Common stock issued, value Lessee, Leases [Policy Text Block] Leases Accounting Standards Update [Axis] Accounting Standards Update Accrued Liabilities, Current Accrued liabilities Total Stockholders' Equity Attributable to Parent [Abstract] Stockholders’ equity Gain (loss) from foreign currency Foreign Currency Transaction Gain (Loss), before Tax Foreign Currency Transaction Gain (Loss), before Tax, Total Foreign currency transaction gain Counterparty Name [Axis] Counterparty Name Entity Address, Address Line Two Entity Address, Address Line Two Reduction in number of common stock capital shares available for future issuance. Reduction in Number of Common Stock Capital Shares Available for Future Issuance Reduction in number of common stock shares available for future issuance Award Type [Axis] Award Type Other Noncash Income (Expense) Other non-cash expenses Other Noncash Income (Expense), Total Other Nonoperating Income (Expense) Finance expense, net Other Nonoperating Income (Expense), Total Long-Term Debt, Current Maturities Current portion of long-term debt Long-term Debt, Current Maturities, Total Research and Development Expense Research and development, net Research and Development Expense, Total Lessee, Operating Lease, Liability, to be Paid Total remaining lease payments Two thousand nineteen omnibus incentive plan. Two Thousand Nineteen Omnibus Incentive Plan [Member] 2019 Omnibus Equity Incentive Plan [Member] Lessee, Operating Lease, Term of Contract Lessee, operating lease, term of contract Pharmaceutical company. Pharmaceutical Company [Member] Pharmaceutical Company [Member] Entity Central Index Key Entity Central Index Key Israel Ministry of Health [Member] Israel Ministry of Health [Member] Israel ministry of health. Accounting Policies [Abstract] Disaggregation of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares available Share-Based Payment Arrangement [Text Block] Share-Based Compensation Expense General and Administrative Expense General and administrative General and Administrative Expense, Total Research and Development Expense [Member] Research and Development [Member] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use asset obtained in exchange for lease liabilities Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Retained Earnings [Member] Accumulated Deficit [Member] Security Deposit Security deposit Gain (loss) from equity-method investment Income (Loss) from Equity Method Investments Income (Loss) from Equity Method Investments, Total Loss (gain) from equity-method investment Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease Liability Current Statement Of Financial Position [Extensible List] Property, Plant and Equipment, Gross Property and equipment, gross Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Additional Paid in Capital Additional paid-in capital Additional Paid in Capital, Total Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Ending Balance Entity Interactive Data Current Entity Interactive Data Current Related Party Transactions Disclosure [Text Block] Related Party Transactions Payment received first installment. Payment Received First Installment Received first installment Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing activities Related Party Transactions [Abstract] Lessee, Operating Lease, Liability, to be Paid, Year One 2023 Lessee Operating Lease Liability Payments Due Next Twelve Months, Total Leasehold Improvements [Member] Leasehold improvements [Member] Local Phone Number Local Phone Number Final payment of disbursement amount. Final Payment Of Disbursement Amount Final payment of disbursement amount Long-Term Debt [Member] Long-term Debt [Member] Debt Disclosure [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Lease Contractual Term [Axis] Lease Contractual Term Commitment and contingencies. Commitment And Contingencies [Table] Commitment And Contingencies [Table] Disaggregation of Revenue [Table Text Block] Schedule of Revenue Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums Loan origination fee paid Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums, Total Income Statement Location [Domain] Income Statement Location Long-Term Debt, Maturity, Year One 2023 Non-refundable payment received. Non Refundable Payment Received Non-refundable payment received mRNA technology. M R N A Technology [Member] mRNA Technology [Member] Property, Plant and Equipment [Abstract] Long-Term Debt Long-term debt Total Shares, Outstanding Balance (in shares) Balance (in shares) Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expense and other assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Share Price Share price Document Fiscal Year Focus Document Fiscal Year Focus Lessee, Operating Lease, Liability, to be Paid, Year Two 2024 Net loss per share, basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Schedule of summary of significant accounting policies. Schedule Of Summary Of Significant Accounting Policies [Table] Schedule Of Summary Of Significant Accounting Policies [Table] Assets [Abstract] Assets Increase (Decrease) in Accrued Liabilities Accrued liabilities Increase (Decrease) in Accrued Liabilities, Total The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable. Prepaid Expenses And Other Receivables Prepaid expenses and other current assets Debt Instrument, Face Amount Term loan Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset SINGAPORE Singapore Economic Development Board [Member] Liabilities and Equity [Abstract] Liabilities and stockholders’ equity Royalty payment percentage. Royalty Payment Percentage Royalty payment percentage of proceeds from net sales Assets, Current [Abstract] Current assets: Disbursed amount upon execution of amendment. Disbursed Amount Upon Execution Of Amendment Disbursed amount upon execution of amendment Underlying agreement. Underlying Agreement [Member] Underlying Agreement [Member] Debt instrument interest only payment extended maturity date. Debt Instrument Interest Only Payment Extended Maturity Date Loan interest-only payment extended maturity date Joint ventures, equity method investments and variable interest entities. Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block] Joint Ventures, Equity Method Investments and Variable Interest Entities Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities Related Party Transaction [Line Items] Related Party Transaction [Line Items] Cover [Abstract] Product and Service [Domain] Product and Service Foreign Currency Transaction Gain (Loss), Realized Foreign currency transaction gain Liabilities, Current [Abstract] Current liabilities: Maximum [Member] Maximum [Member] Disbursement payment upon achievement of required manufacturing practices and IND application. Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application Disbursement payment upon achievement of required manufacturing practices and IND application Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Furniture and Fixtures [Member] Office equipment and furniture [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options (in shares) Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Schedule of Share-based Compensation Expenses Debt Instrument, Basis Spread on Variable Rate Interest of the prime rate plus Long-Term Debt, Maturity, Remainder of Fiscal Year 2022 Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Segment Reporting, Policy [Policy Text Block] Segment Information Contract With Customer Liability Additions For Advanced Billings Contract With Customer Liability Additions For Advanced Billings Contract Liabilities, Additions for advanced billings Common Stock, Shares Authorized Common stock, shares authorized Trading Symbol Trading Symbol Acquisition of research and development in process through issuance of common stock. Acquisition Of Research And Development In Process Through Issuance Of Common Stock Acquisition of in-process research and development through issuance of common stock Grant receivable number of installments. Grant Receivable Number Of Installments Grant, number of installments Disbursement period one. Disbursement Period One [Member] Disbursement Due January 2020 [Member] Disbursement amount payable upon achievement of project goal. Disbursement Amount Payable Upon Achievement Of Project Goal Disbursement amount payable upon achievement of project goal Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Grant two. Grant Two [Member] Grant 2 Debt instrument interest only payment extended period. Debt Instrument Interest Only Payment Extended Period Extension to interest only period Plan Name [Axis] Plan Name Schedule of Related Party Transactions, by Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Accrued cystic fibrosis foundation liability. Accrued Cystic Fibrosis Foundation Liability Cystic Fibrosis Foundation Liability (Note 9) Axcelead, Inc. Axcelead Inc [Member] Axcelead, Inc [Member] Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee Common Stock, Par or Stated Value Per Share Common stock, par value Stock Issued During Period, Shares, Acquisitions Issuance of common stock related to acquired in-process research and development (in shares) Other collaboration agreements. Other Collaboration Agreements [Member] Other Collaboration Agreements [Member] Stock Issued During Period, Value, Acquisitions Issuance of common stock related to acquired in-process research and development Debt Instrument [Line Items] Debt Instrument [Line Items] Long-Term Debt, Type [Domain] Long-term Debt, Type Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share ISRAEL Israeli Ministry of Health ("MOH") [Member]